In order to maintain good eye health, supporting healthy retinal function becomes utmost importance because good vision is critical to everyday function.
Glaucoma is one of the leading causes of blindness and visual impairments, affecting 1 in 200 people aged fifty and younger, and 1 in ten over the age of eighty. There are two main types of glaucoma: open-angle glaucoma and closed-angle glaucoma. Open-angle glaucoma accounts for 90% of glaucoma cases in the United States while closed-angle glaucoma accounts for less than 10%. In other nations, particularly Asian countries, the close-angle glaucoma accounts for as many as half of glaucoma cases.
Scientists have recently found beta-amyloid (Aβ) in the retina of glaucoma patients where Aβ deposits cause retinal ganglion cell death, suggesting that if we can eliminate the accumulation of Aβ in the retina, we may be able to prevent the onset of glaucoma
How Does Ocu-Xyl™ Work?
As we now know Aβ as one of the causes of the onset of glaucoma and AMD, the onset of glaucoma and AMD may be resolved by:
- removing the aggregated Aβ in the retina,
- preventing the accumulation of Aβ in the retina,
- protecting retina cells from Aβ toxicity,
- repairing the damaged retinal cells, and
- increasing retinal cell viability.
Age-related Macular Degeneration (AMD)
AMD is another disease in the eye that causes blindness and visual impairments in older adults (>50 years). AMD is characterized by the formation of drusen, extracellular deposits associated with atrophy of the retinal pigmented epithelium (RPE) that cause disturbance in the trans-epithelial barrier to result in photoreceptor death in the macula between the retinal pigment epithelium and the underlying choroid. Approximately 10% of population between 66 to 74 years of age show signs of macular degeneration, that increases to 30% of population 75 to 85 years of age.
AMD occurs in “dry” and “wet” forms. In the dry form of AMD, drusen accumulates between the retina and the choroid to cause atrophy to the retinal pigment epithelial layer below the retina to cause vision loss through loss of photoreceptors (rods and cones) in the macula of the eye.
In the wet form of AMD, which is more severe but only accounts for about 10% of the AMD patients, blood vessels grow from the choroid behind the retina to cause detachment of retina to result in acute vision loss. In the drusen of AMD, an excess extracellular Aβ deposits, that is one of the leading causes of AD and glaucoma, was found along with characteristic degeneration of photoreceptors in the retina. This finding suggests that if we can eliminate the accumulation of Aβ in the drusen, we may be able to prevent the onset of AMD.
Ocu-Xyl™ of Core LifeSource Inc. is 100% natural.
Serving Size 1 capsule (Approx. ~760 mg)
Turmeric (Curcuma longa) ~250mg
Ginger (Zingiber officinale) ~220 mg
Cinnamon (Cinnamomum zeylanicum) ~100mg
Scutellaria baicalensis ~75mg
Piper nigrum ~60mg
Calendula officinalis ~55mg
*Daily Values (%DV) are not established.
Turmeric, Ginger, Cinnamon, S. baicalensis, P. nigrum, C. officinalis, vegetable capsule
Adults – As a dietary supplement, take 1~2 capsules two times daily, preferably with a meal.
Pregnant women and MAO inhibitor users should not take this product. Use of this product is not intended to replace regular visit to your physician. Keep this product out of reach of children.
Tamper evident seal under cap. Do not use if protective seal is broken or missing. Store at room temperature, tightly closed. Avoid excessive heat and humidity.
Sugar, salt, preservatives, artificial flavor or color, starch, milk, egg, corn, wheat, yeast, soy.
This is a specially processed product made from turmeric, ginger, cinnamon, P. nigrum, S. baicalensis, and C. officinalis using GLL Corp’s proprietary technology. This product contains patent protected compounds and antioxidants GXC-00105, GXC-00124, GXC-00242, GXC-00273, GXC-00288,
GXC-00312 etc. that have shown to protect cells in the eyes from bête-amyloid, which has been identified as one of the culprits of retinal cell atrophy-related diseases
The formulation, and the claims thereof are exclusive properties of the product
U.S. 6,887,898; 7,279,501; 7,282,523; 7,572,829; 7,728,043 and other patents pending.
This is a product of GLL Corp.
Core LifeSource, Inc., Rolling Meadows, IL 60008
MADE IN USA.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.